Status:
RECRUITING
MRE for Diagnosis of Pancreatic Masses
Lead Sponsor:
Yu Shi
Conditions:
Pancreatic Neoplasm
Magnetic Resonance Imaging
Eligibility:
All Genders
18-80 years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic o...
Detailed Description
Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic o...
Eligibility Criteria
Inclusion
- granting of written informed consent
- age ≥18 years
- no history of extrapancreatic malignancy
- no preoperative biliary drainage
- definitive histologic evidence of PDAC in excisional biopsy
- with no less than three months of postoperative mortality or six months of follow- up
Exclusion
- inability to re-review of tissue specimens
- unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection
- tumor diameters \<1.0 cm
- withdrawal/dropout during follow-up
Key Trial Info
Start Date :
October 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06526442
Start Date
October 9 2020
End Date
June 1 2026
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing hospital of china medical university
Shenyang, Liaoning, China, 110004